



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/918,951
				Filing Date	August 21, 2002
				First Named Inventor	David Alland
				Art Unit	1645
				Examiner Name	TBA
				Attorney Docket Number	96700/680
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	8-30-03
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-7)
Approved for use through 10/31/2002. OMB 0651-0047
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/918,951		
		Filing Date	August 21, 2002		
		First Named Inventor	David Alland		
		Group Art Unit	1645		
		Examiner Name	TBA		
Sheet	2	of	2	Attorney Docket Number	96700/680

RECEIVED
AUG 26 2002
FEDERAL CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DAW	1	ALTSCHUL et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25:3389-3402, 1997.	
DAW	2	BAIROCH et al., The PROSITE database, its status in 1997. Nucleic Acids Res., 25:217-221, 1997.	
DAW	3	BANERJEE et al., inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 263:227-230, 1994.	
DAW	4	COLE et al., Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 393:537-544, 1998.	
DAW	5	de SAIZIEU et al., Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays. Nature Biotech., 16:45-48, 1998.	
DAW	6	GARBE et al., Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40:1754-1756, 1996.	
DAW	7	KINGER and TYAGI, Identification and cloning of genes differentially expressed in the virulent strain of Mycobacterium tuberculosis. Gene, 131:113-117, 1993.	
DAW	8	MATHIOPOULOS and SONENSHEIN, Identification of Bacillus subtilis expressed early during sporulation. Mol. Microbiol., 3:1071-1081, 1989.	
DAW	9	MDLULI et al., Inhibition of a mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science, 280:1607-1610, 1998.	
DAW	10	PLUM and CLARK-CURTISS, Induction of Mycobacterium avium gene expression following phagocytosis by human macrophages. Infect. and Immun. 62:476-483, 1994.	
DAW	11	WONG and McCLELLAND, Stress-inducible gene of Salmonella typhimurium identified by arbitrarily primed PCR of RNA. Proc. Natl. Acad. Sci. USA, 91:639-643, 1994.	

Examiner Signature	<i>R.P. Swan</i>	Date Considered	8-25-03
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.